Xtl Biopharmaceuticals (XTLB) Income from Discontinued Operations (2014 - 2015)
Xtl Biopharmaceuticals (XTLB) posted quarterly Income from Discontinued Operations of 1.0 for Q4 2015, down 200.0% year-on-year from 1.0 in Q4 2014, and up 50.0% on a QoQ basis from 2.0 in Q1 2015.
Xtl Biopharmaceuticals (XTLB) Income from Discontinued Operations (2014 - 2015) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Income from Discontinued Operations for 2 consecutive years, with 1.0 the latest figure, recorded in Q4 2015.
- Quarterly Income from Discontinued Operations fell 200.0% year-over-year to 1.0 in Q4 2015, while the trailing twelve-month figure through Dec 2015 was 3.0 (changed N/A YoY) and the FY2015 annual result came in at 3.0, down 50.0% from the prior year.
- Income from Discontinued Operations climbed to 1.0 in Q4 2015 per XTLB's latest filing, from 2.0 in the prior quarter.
- Over the last five years, Income from Discontinued Operations for XTLB reached as high as 1.0 in Q4 2014 and fell as low as 2.0 in Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | - |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | -1.00 |
| Mar 31, 2015 | -2.00 |
| Dec 31, 2014 | 1.00 |
| Sep 30, 2014 | -2.00 |
| Jun 30, 2014 | -1.00 |